COTELLIC is a prescription medicine that is used with the medicine ZELBORAF, to treat melanoma:
- Vemurafenib blocks the activity of a mutated form of a molecule called BRAF. Cobimetinib blocks the activity of a molecule called MEK. BRAF and MEK are protein molecules that are important in regulating cell growth.The BRAF V600E and V600K mutations signal cells to grow abnormally and divide out of control. These cells can become a melanoma tumor. About half of all melanomas have a BRAF mutation. MEK receives signals from BRAF and other molecules in the cell. In melanoma treatment, researchers have found that blocking BRAF and MEK at the same time is more effective than blocking MEK alone.The combination of vemurafenib and cobimetinib interferes with abnormal BRAF signals to slow or stop the out-of-control cell growth:
- Vemurafenib blocks the signaling pathway of the V600E-mutated BRAF molecule.
- Cobimetinib blocks signaling from the V600E- or V600K-mutated BRAF molecule via the MEK molecule.
- for more information visit Roche Canada
Manitoba – September 28, 2017
Cotellic in combination with Zelboraf has been listed in Manitoba
New Brunswick – September 25, 2017
Cotellic in combination with Zelboraf has been listed in New Brunswick.
Dr. Marcus Butler
Expanding Horizons in Melanoma Treatment
Dr. Marcus Butler cares for patients with melanoma and gynecologic malignancies and is the Clinical Head of the Immune Monitoring Team at Princess Margaret Cancer Centre.
His work focuses on the development of immunotherapy trials, which include studies, alone and in combination, of immune checkpoint blocking antibodies, immunomodulators, and adoptive cell transfer.